PTGX Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -41.15% compared to Protagonist Therapeutics's net margin of 24.92%. Protagonist Therapeutics's return on equity of 9.37% beat Biomarin Pharmaceutical's return on equity of 9.62%.

Protagonist Therapeutics has a consensus price target of $68.70, signalling upside risk potential of 55.18%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.02 which suggests that it could grow by 60.62%. Given that Biomarin Pharmaceutical has higher upside potential than Protagonist Therapeutics, analysts believe Biomarin Pharmaceutical is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.650, which suggesting that the stock is 165.017% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $28.3M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Protagonist Therapeutics's net income of -$11.7M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 59.03x while Biomarin Pharmaceutical's PE ratio is 22.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 13.45x versus 4.01x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Checkpoint Therapeutics has a net margin of -41.15% compared to Protagonist Therapeutics's net margin of -16268.29%. Protagonist Therapeutics's return on equity of 9.37% beat Checkpoint Therapeutics's return on equity of --.

Protagonist Therapeutics has a consensus price target of $68.70, signalling upside risk potential of 55.18%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 4.42%. Given that Protagonist Therapeutics has higher upside potential than Checkpoint Therapeutics, analysts believe Protagonist Therapeutics is more attractive than Checkpoint Therapeutics.

Protagonist Therapeutics has a beta of 2.650, which suggesting that the stock is 165.017% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.179, suggesting its more volatile than the S&P 500 by 17.928%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $28.3M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Protagonist Therapeutics's net income of -$11.7M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 59.03x while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 13.45x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -41.15% compared to Protagonist Therapeutics's net margin of 19.72%. Protagonist Therapeutics's return on equity of 9.37% beat Gilead Sciences's return on equity of 32.29%.

Protagonist Therapeutics has a consensus price target of $68.70, signalling upside risk potential of 55.18%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 13.42%. Given that Protagonist Therapeutics has higher upside potential than Gilead Sciences, analysts believe Protagonist Therapeutics is more attractive than Gilead Sciences.

Protagonist Therapeutics has a beta of 2.650, which suggesting that the stock is 165.017% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.06% to investors and pays a quarterly dividend of $0.79 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $28.3M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Protagonist Therapeutics's net income of -$11.7M is lower than Gilead Sciences's net income of $1.3B. Notably, Protagonist Therapeutics's price-to-earnings ratio is 59.03x while Gilead Sciences's PE ratio is 21.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 13.45x versus 4.45x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -41.15% compared to Protagonist Therapeutics's net margin of 50.24%. Protagonist Therapeutics's return on equity of 9.37% beat Johnson & Johnson's return on equity of 30.18%.

Protagonist Therapeutics has a consensus price target of $68.70, signalling upside risk potential of 55.18%. On the other hand Johnson & Johnson has an analysts' consensus of $169.29 which suggests that it could grow by 14.04%. Given that Protagonist Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Protagonist Therapeutics is more attractive than Johnson & Johnson.

Protagonist Therapeutics has a beta of 2.650, which suggesting that the stock is 165.017% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.34% to investors and pays a quarterly dividend of $1.24 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Protagonist Therapeutics quarterly revenues are $28.3M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Protagonist Therapeutics's net income of -$11.7M is lower than Johnson & Johnson's net income of $11B. Notably, Protagonist Therapeutics's price-to-earnings ratio is 59.03x while Johnson & Johnson's PE ratio is 16.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 13.45x versus 4.03x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.